On May 2, 2025 Zonhon Biopharma Institute reported the Investigational New Drug (IND) application for ZHB114 for Injection—a Class I innovative biologic drug independently developed by Zonhonbio with proprietary intellectual property rights—was officially approved by the U.S. Food and Drug Administration (FDA) (Press release, Zonhon Biopharma Institute, MAY 2, 2025, View Source [SID1234656085]). The newly approved indication covers advanced malignant tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!